Conclusions-Platinum sensitivity status may no longer be strongly associated with PFS or OS in at least one multivariate model. Validation of prognostic risk groups identified here is warranted. These data have critical implications in the design of future SCLC trials.
Background
Disease progression after initial platinum-based chemotherapy is almost universal in patients with extensive stage small cell lung cancer (ES-SCLC). [1] At the time of progression, patients have traditionally been categorized as either platinum-sensitive (defined as progression > 90 days from last platinum dose) or platinum-refractory (progression < 90 days from last platinum dose). Patients who progress while receiving platinum-based therapy are sometimes labeled as "platinum-resistant"; however, many clinicians likewise define these patients as "platinum-refractory" as well.
The practice of categorizing patients according to platinum sensitivity status arose from observations in a phase II trial of the investigational cytotoxic agent teniposide [2] . In this trial that accrued 50 previously-treated SCLC patients, longer time from prior chemotherapy discontinuation (i.e., >2.6 months) and response to prior chemotherapy were found to be associated with response to subsequent teniposide.
Since those seminal observations, subsequent efficacy trials in SCLC began accounting for platinum-sensitivity status. In many cases, this resulted in more complex studies, higher sample sizes and increased resource use. Some studies opted to solely focus on the platinum sensitive group, excluding those with refractory disease [3, 4] . In SWOG, trials in previously treated SCLC since 2000 have mandated independent accrual to platinum sensitive and refractory strata in order to account for the possibility of differential outcomes to investigational therapies between these groups. However, recent trials (both SWOG and non-SWOG) have not shown divergent outcomes related to platinum-sensitivity status [5] [6] [7] [8] [9] .
In the past decade, SWOG has conducted three phase II trials of investigational regimens in platinum-treated SCLC (S0802, S0435, and S0327); these trials are summarized in Table 1 [5] [6] [7] . In these studies, progression free survival (PFS) and overall survival (OS) were generally comparable between platinum-sensitive and refractory strata across all trials, except for S0802 where modest advantage for PFS and OS in the aflibercept-containing arm was demonstrated. Similarly, the final results of a recent non-SWOG phase II trial of temozolamide in platinum-treated SCLC also showed no clear differences in outcomes dependent on platinum sensitivity status [10] . We therefore sought to evaluate the association between platinum sensitivity status and SCLC patient outcome in the modern era using the pooled SWOG database.
Methods
Updated patient-level data from S0802, S0435, and S0327 were pooled. S0802 randomized patients to either topotecanalone or topotecan plus the angiogenesis inhibitor aflibercept (VEGF-Trap). S0435 was a single arm trial of the VEGFR-TKI sorafenib. S0327 was a single arm trial of the proteasome inhibitor PS-341 (bortezomib). Each of the trials had consistent eligibility criteria and collected the same baseline demographic variables. The primary endpoint for S0802 was 3-month PFS, while the primary endpoint for S0435 and S0327 was response rate. All staging definitions used by SWOG for these trials preceded the 7 th edition of the TNM staging system. All studies were reviewed and approved by Institutional Review Boards and all patients gave written informed consent.
Multivariate Cox regression models were fit to assess the relationship between baseline characteristics and PFS and OS. Progression-free and OS estimates were calculated using the method of Kaplan-Meier. Confidence intervals for the median were constructed using the method of Brookmeyer-Crowley. All p-values were two-sided. To investigate a predictive model for OS, recursive partitioning was performed using the likelihood tree model of LeBlanc and Crowley [11] . The minimum node size was set at 20.
Overall survival was defined as the duration from the date of enrollment to the date of death due to any cause. Patients last known to be alive were censored at the date of last contact. Progression-free survival was defined as the duration from the date of enrollment to the date of first documentation of disease progression, as defined by RECIST, symptomatic deterioration without documented disease progression, or death due to any cause. Patients last known to be alive and without evidence of disease progression or symptomatic deterioration were censored at the date of last contact. Disease assessments were performed every 6 weeks in all 3 protocols.
Results
Three hundred twenty-nine patients constituted the pooled study population. Patient characteristics stratified by platinum sensitivity status are summarized in Table 2 . Of 329 patients, 151 were categorized as platinum-sensitive while 178 were platinum-refractory. Median age was 63 years. Males comprised 52% of the group while those with performance status 1 constituted 67%. There were 89 (28%) patients with clinically significant weight loss of >= 5% within the preceding 3 months. Elevated LDH levels were seen in 43%.
Crude unadjusted analysis of PFS and OS stratified by platinum sensitivity status are summarized in Figure 1 . The hazard ratio for PFS (refractory/sensitive) was 1.0 (95% CI 0.81, 1.25), with a p-value of 0.98. The hazard ratio for OS (refractory/sensitive) was 1.24 (95% CI 0.99, 1.57), with a p-value of 0.06. (Table 3 ) showed that only elevated LDH (HR 1.83, p<0.0001) and trial assignment to S0802 (HR 1.82, p=0.001) were independently prognostic for PFS. In contrast, platinum sensitivity status was not associated with PFS. Multivariate analysis for OS (Table 4 ) showed that platinum sensitivity status was also not associated with OS (HR 1.25, p=0.14). Instead, elevated LDH (HR 2.04, p<0.0001), weight loss (HR 1.53, p=0.01), performance status of 1 (HR 1.43, p=0.02), and male sex (HR 1.36, p=0.04) were found to be the only clinical variables associated with worse OS. In a subsequent analysis, 14 patients (6 from S0435 and 8 from S0802) had their prior chemotherapy status changed from 2 or more to exactly one. An additional 3 patients (2 on S0435 and 1 on S0802) who had missing data were assumed to have received exactly one prior chemo regimen. (The eligibility criteria stated that these patients must have received exactly one prior regimen when all 17 of these patients were enrolled). When these 17 patients who had exactly one prior chemotherapy were reclassified, multivariate analysis subsequently showed that prior chemotherapy was significantly associated with improved OS (HR 0.29, p=0.03). Sex, LDH, weight loss, and performance status remained significantly associated with OS; however, the rest of the variables (including platinum sensitivity status) remained not to be significantly associated with OS. We then analyzed the data excluding the remaining 36 patients who received more than one prior chemotherapy regimen. In this analysis, platinum refractory status becomes associated with OS (HR 1.35, 95% CI 1.00-1.82, p=0.049). There were no substantial changes seen in the PFS multivariate model.
Multivariate analysis of baseline clinical variables and PFS
Recursive partitioning analysis showed that specific subsets of patients had differential outcomes dependent on the distribution of baseline clinical variables (Figure 2 ). Prognostic groups consisting of low, intermediate, and high risk subsets were identified based on differential median OS outcomes of 8, 5, and 2.4 months, respectively (Figure 3 ), using elevated LDH, >= 5% weight loss, performance status of 1, and male sex as risk factors. Specifically, high risk patients had 2 risk factors (elevated LDH and either >= 5% weight loss or Zubrod performance status > 0), intermediate risk patients had 1 risk factor (either male sex or elevated LDH if not already in high risk group), and low risk patients had no risk factors (i.e., they had normal LDH and were female). A practical model for identifying these subjects is provided in Table 5 , representing a modern classifier that no longer includes platinum-sensitivity status as a prognostic indicator.
Discussion
In this modern SWOG database analysis, platinum sensitivity status was not significantly associated with survival from the time of post-platinum progression. However, in an unplanned analysis that excluded 36 patients who received >1 prior chemotherapy regimen, platinum sensitivity status was found to be associated with OS. Nevertheless, factors prognostic for survival in this pooled analysis included elevated LDH, weight loss, poor performance status, and male sex.
These results are divergent from prior studies in this context [12] and particularly, from the recent results of a randomized study comparing amrubicin with topotecan in which 637 relapsed SCLC patients were randomized 2:1 to either amrubicin or topotecan [13] . The topline results of that trial showed that despite a higher response rate in the amrubicin arm (31 vs 17%, p=0.0002), there was no apparent difference in overall survival (HR 0.88, p=0.17). Nonetheless, there was an apparent divergence in OS dependent on platinum refractory status. There were 342 patients in the "sensitive" group compared to 295 patients in the "refractory group". The former group had better median OS (9.2 months for amrubicin arm; 10 months for the topotecan arm) when compared to the latter group (6.2 months in the amrubicin arm, 5.7 months for the topotecan arm).
The lack of more contemporary consensus information on the value of prospectively stratifying SCLC patients with relapsed disease according platinum-refractory status suggests that this practice ought to be revisited, particularly with regard to phase II drug development. In this context, new agent development often relies on intermediate endpoints such as response rate or PFS to determine whether to proceed to phase III. As reported here, the various phase II agents employed in each of the trials did not yield differential outcomes according to pre-specified strata based on platinum-sensitivity, showing that this differentiation has limited prognostic significance (ie., where survival outcomes are independent of treatment received). A priori, we would have expected to see PFS and OS differences based on historical data on platinum-sensitivity status.
Given the failure of platinum refractory status to provide statistically significant prognostic information in this study, we attempted to develop a new prognostic model based on the best available information from the SWOG database. If validated in an independent pooled dataset containing the same clinical variables described herein, the resulting model will have potential relevance for clinical practice and trial design. We identified clinically relevant prognostic risk groups by recursive partitioning analysis that stratified patients into low, intermediate, and high risk groups based on expected OS outcomes. These risk groupings are potentially useful for individualized patient counseling in clinic and perhaps stratification of patients in prospective phase II trials while remaining agnostic to platinumsensitivity status. However, it will be necessary to perform a validation study of these risk groupings in an independent SCLC dataset prior to wide use.
This pooled study is limited by its retrospective nature and the heterogeneity of investigational therapies employed in the individual trials. We acknowledge the trials included in this analysis had no or little activity in this disease; therefore, we cannot rule out the possibility that platinum sensitivity status may influence outcome in the context of active therapies. It must be emphasized that this study focused solely on the prognostic value of platinum sensitivity (again, independent of treatment received) and not its predictive value. Nonetheless, the therapeutic effect identified in each of the trials was absent or small, reducing the likelihood that an interaction between platinum refractory status and treatment could have biased our results. Additionally, we lack molecular characterization of the tumors that may be needed to develop a robust prognostic system. The strengths of this analysis include the consistent collection of relevant baseline variables, its relatively robust sample size, and the relative homogeneity of protocol design inherent in SWOG trials.
Conclusion
In this modern SCLC database, platinum sensitivity status may no longer be as strongly associated with PFS and/or OS, calling into question its use in future prospective trials in ES-SCLC. Baseline PS, sex, LDH, and weight loss remain the only independent prognostic indicators of OS outcomes. Here we developed a simple prognostic scoring system from these data that, if validated, would better define prognostic subgroups in the clinic and in future studies. Recursive Partitioning Analysis of Platinum-Treated Small Cell Lung Cancer 
